Thinking about it some more: this stock is toast. Axiron was already under fire from the FDA's warning, but we consoled ourselves with the idea that we had the best product in the market and that we'd hold market share, which we did. Not that it helped the SP very much.
Now, our competitive position within what was already a shrinking market has basically been destroyed in a single stroke.
Lily is suddenly going to be in a position to negotiate a MUCH tougher agreement, and we're going to be stuck in a 'like it or lump it' situation.
Our net cash position is going to be quickly chewed up by our pipeline, so any support to the SP that it might provide isn't going to last.
I think that we're back to being a blue-sky biotech.
ACR Price at posting:
46.0¢ Sentiment: Sell Disclosure: Not Held
